Aeroallergen immunotherapy associated with reduced risk of severe COVID-19 in 1095 allergic patients.

ABSTRACT:

Introduction

Allergen immunotherapy (AIT) brings along changes in the immune system, restoring dendritic cell function, reducing T2 inflammation and augmenting the regulatory cell activation. Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, interferes with the immune system causing immune suppression during the first phase and over-activation in more advanced disease. We decided to explore the interaction of both in a real-world observational trial.

Methods

We registered COVID-19 outcomes in patients with allergic disorders in Latin America, treated with and without AIT. The registry was conducted during the first 1.3 years of the pandemic, with most of the data collected before COVID-19 vaccination was conclu

SUBMITTER: Larenas-Linnemann D 

PROVIDER: S-EPMC10154540 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature